We’re proud to announce a new collaboration with Dak Prescott’s Faith Fight Finish Foundation and the Partners in Wellness program—an initiative of LSU Health Shreveport and Ochsner LSU Health—Feist-Weiller Cancer Center—to help increase colorectal cancer screening rates in northern and central Louisiana. As part of this effort, the Partners in Wellness mobile screening program will offer our Shield? blood test at events throughout the region during #ColorectalCancerAwarenessMonth, making colorectal cancer screening more accessible and convenient for underserved communities. Together, we’re bringing critical screening options directly to the communities that need them most—because early detection can save lives. More details: https://lnkd.in/e5ucrjmB
关于我们
Guardant Health is a leading precision medicine company focused on guarding wellness and giving every person more time free from cancer. Founded in 2012, we're transforming patient care by providing critical insights into what drives disease through its advanced blood and tissue tests, real-world data and AI analytics. Guardant Health has commercially launched Guardant360?, Guardant360? CDx, Guardant360 TissueNext?, Guardant360 Response?, and GuardantINFINITY? tests for advanced-stage cancer patients, and Guardant Reveal? for early-stage cancer patients. The Guardant Health screening portfolio, including the FDA-approved Shield? test, aims to address the needs of individuals eligible for cancer screening. Important Note for Job Applicants: Guardant Health is aware of recruiting scams where unauthorized individuals use the company's name in fraudulent emails, job postings, and social media messages. Please note that Guardant Health will never ask for money or credit card information during the job application process, nor does the company communicate with candidates via online chatrooms or personal email accounts such as Gmail or Hotmail.
- 网站
-
https://guardanthealth.com/
Guardant Health的外部链接
- 所属行业
- 生物技术研究
- 规模
- 1,001-5,000 人
- 总部
- Palo Alto，California
- 类型
- 上市公司
- 创立
- 2012
地点
Guardant Health员工
动态
-
We’re proud to collaborate with the?European Coalition for Comprehensive Genomic Profiling (ECGP) initiative to improve patient access and help make comprehensive genomic profiling (CGP) a routine part of cancer care across Europe!
???Let’s unlock the untapped potential of #ComprehensiveGenomicProfiling (CGP)! We are thrilled to announce the publication of our recommendations on how to improve patient access to CGP:?"The untapped potential of Comprehensive Genomic Profiling"! These recommendations are developed by ECGP in collaboration with their renowned independent experts and patient advocate Steering Group. Patient access to comprehensive genomic profiling across Europe remains limited due to various challenges. Through our recommendations, we outline strategies and actionable insights to address them: ????ECGP recommendations ?? Improve?awareness?on the value of Comprehensive Genomic Profiling (CGP) ?? Establish clear?funding and reimbursement pathways?for technologies like CGP ?? Ensure the?implementation requirements?are realised to ensure patient access to CGP, guidelines, (data) infrastructure, sufficient and capable workforce and stimulating procurement policies. ?? Enhance?collaboration?among policymakers, industry, healthcare professionals, and patient advocacy groups, to improve access to CGP ?? Read the recommendations here: https://lnkd.in/es4eC6ME Join us in our mission to unlock the potential of personalized medicines by increasing access to comprehensive genomic profiling! Feel free to connect with Matias Olsen to further discuss this topic. Find out more about ECGP: https://ecgp.eu/ Amgen Guardant Health Illumina Labcorp Menarini Stemline MSD Vintura #AdvancedDiagnostics #GenomicProfiling #ADx #HealthcareInnovation #ECGP #PatientAccess #EUCOPE #HealthEquity #CGP
-
-
In honor of #ColorectalCancerAwarenessMonth, join us for a special webinar series diving into the latest data from the groundbreaking GOZILA study conducted in Japan. Together, we’ll explore key insights from the 2024 Nature Medicine publication, “Targeted therapy guided by circulating tumor DNA analysis in advanced gastrointestinal tumors” by Nakamura et al., and discuss how this evolving data is shaping the future of precision oncology for colorectal and other gastrointestinal (GI) cancers. ???Webinar Dates & Times: March 11: 12:30pm - 1:00pm ET |?https://bit.ly/41JuxbG March 12: 1:00pm - 1:30pm ET?| https://bit.ly/4ioZ0kM March 12: 7:30pm - 8:00pm ET?| https://bit.ly/4boZGUU March 13: 6:00pm - 6:30pm ET?| https://bit.ly/4irOlpr
-
-
Today marks the start of Colorectal Cancer Awareness Month! A time to come together with partners and communities to support those affected and emphasize the critical role of early detection and screening in the fight against #ColorectalCancer. #ColorectalCancerAwarenessMonth #EarlyDetectionMatters #GetScreened
-
-
Over the past few weeks, our Oncology and Screening teams came together for their annual National Sales Meetings — an incredible opportunity to align on strategy, sharpen skills, and celebrate 2024 achievements. With great energy and a shared focus, our teams are ready to embrace the new year and the opportunities ahead, driven by our mission to conquer cancer with data and a relentless commitment to patients. We’re proud to have such a dedicated team representing Guardant in the field. #ChallengeAccepted #OneGuardant
-
-
Today, we announced findings from our second annual “Closing the Gap: CRC Screening Insights” survey, conducted by The Harris Poll. ? The survey confirms that fear and anxiety about the #ColorectalCancer screening process could keep millions of Americans from getting screened — but it also highlights a promising solution. Both doctors and patients agree that having an FDA-approved blood test option, like Shield?, could help more people complete screening, which could potentially save more lives. Explore the full findings: https://lnkd.in/efJUnENT
-
-
We’re proud to be a sponsor of the 9th Annual Liquid Biopsy for Precision Oncology Summit next week in San Diego. Join our plenary session with Amar Das, MD, PhD, FACMI to learn how GuardantINFORM, our real-world data platform,?supports every phase of drug development. Plus, discover how Guardant Infinity's innovative methylation technology is shaping the future of precision oncology. Event details: https://lbx-summit.com
-
-
On International Day of Women and Girls in Science, we celebrate the incredible women who are breaking barriers, driving innovation, and inspiring the next generation of leaders in #Science and #STEM. Let’s recognize their impact and work towards a future where all women and girls have the opportunity to shine in these fields. #WomenInScience #WomenInSTEM
-
-
We’re proud to share that our Shield? blood test was recently featured on Health Uncensored with Dr. Drew! In the insightful segment, our VP of Clinical Development, Sam Asgarian, MD MBA, sat down with Dr. Drew to discuss the vital importance of early detection and how a more pleasant screening option can help. The segment also highlights John Gormly’s powerful story, showing how a routine screening with the Shield test led to an early diagnosis that changed his life. Watch the full segment: https://lnkd.in/gY5pGnHv